In previous studies, ALK positive NSCLC often developed metastasis, with brain metastasis being the most common, with a baseline cohort metastasis rate of approximately 24% – 29%, followed by bone metastasis of approximately 27% (24–26). Here, ALK is linked to bone metastasis.